PROJECT NUMBER

10599

Cross-strain HIV therapeutic vaccine for all geographical regions

A series of chimeric immunogenic polypeptides developed based on the HIVconsv methodology, capable of inducing robust, effective and cross-strain immunity to HIV, is available and tested in clinical trials.

Applications: HIV therapeutic or prophylactic vaccine



Features	Benefits
First-generation HIVconsvX conserved vaccines delivered by simian adenovirus ChAdV63 and poxvirus MVA showed high immunogenicity across 8 trials in UK, EU and Africa	Wealth of clinical data and knowledge in the development of HIV cross-strain vaccines; Successfully elicit protective potential of killer T cells targeting regions in HIVconsvX
Second-generation tHIVconsvX with conserved protein regions common to global variants delivered by simian adenovirus ChAdOx1 and poxvirus MVA are being tested in a heterologous prime-boost regimen	HIVconsvX vaccine with maximum HIV epitope match that protect against all HIV escape variants; ChAdOx1, a platform used in the Oxford/Astra-Zeneca vaccine for SARS-CoV2, a licensed and proven effective vaccine
Immunogen delivery applicable to other vaccine platforms e.g. RNA	Viable vaccine modalities for effective therapeutic or prophylactic use

Patented and Available for

- Co-development
- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.